Cargando…
Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies
BACKGROUND: Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV in combination with first-line chemotherapy for patients with advanced NSCLC. M...
Autores principales: | Wang, Bo, Xu, Lu, Li, Qihuan, Man, Sailimai, Jin, Cheng, Liu, Lian, Zhan, Siyan, Ning, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579986/ https://www.ncbi.nlm.nih.gov/pubmed/33087103 http://dx.doi.org/10.1186/s12885-020-07527-4 |
Ejemplares similares
-
Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
por: Cheng, Yuan, et al.
Publicado: (2019) -
Therapy with teicoplanin in the ICU: continuous intravenous infusion or intermittent intravenous administration?
por: Nardi, E, et al.
Publicado: (2008) -
A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
por: Han, Bing, et al.
Publicado: (2023) -
Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019) -
Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients
por: Maluangnon, Chailat, et al.
Publicado: (2022)